EZH2 Monoclonal Antibody (AC22), eBioscience™, Invitrogen™

Description

Description: The monoclonal antibody AC22 recognizes EZH2 (Enhancer of zeste homolog 2), a member of the polycomb group (PcG) proteins responsible for repression of gene expression through recognition and modification of histone methylation and chromatin structure. EZH2 comprises the catalytic subunit of the polycomb repressive complex 2 (PRC2) and directly represses gene expression through methylation of histone H3 on lysine 27 (H3K27) as well as direct protein targets such as GATA4. The PRC2 complex gene repression is necessary for proper development and differentiation. Underexpression of EZH2 is linked to abnormal developmental patterning and a loss of stem cell pluripotency, while overexpression of EZH2 is present in many tumors and correlates with poor prognosis in melanoma, breast, and prostate cancer. Applications Reported: This AC22 antibody has been reported for use in immunoprecipitation, western blotting, and immunocytochemistry. Applications Tested: This AC22 antibody has been tested by immunocytochemistry of methanol-fixed cells and can be used at less than or equal to 5 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

EZH2 (Histone-lysine N-methyltransferase) is a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. EZH2 may play a role in the hematopoietic and central nervous systems. Mutations affecting EZH2 can cause Weaver syndrome (WVS).